Studies cancers that spread to the lining of the belly
Observes patients with belly-lining cancers to find markers of recurrence and prognosis.
Plain-language title generated from the registry record
Registry title: Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Key facts
- Where
- Oslo, NorwaySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed cancer on the surface of the abdominal cavity (peritoneum) who are candidates for surgery with heated chemotherapy inside the abdomen (CRS-HIPEC).
- Age
- Older than 18 years (minimum age 18 Years)
- Sex
- All sexes can join.
- Disease stage
- Confirmed peritoneal surface malignancy, and a candidate for CRS-HIPEC (surgery plus heated chemotherapy in the abdomen).
Read by machine on 12 November 2026.
Where in Norway
- The Norwegian Radium HospitalOslo, NorwayContact: Kjersti Flatmark, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT02073500
- Record updated
- 28 July 2021
- Original description
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).Read full original descriptionShow less
Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Inclusion: age > 18 years; confirmed diagnosis of peritoneal surface malignancy; candidate for CRS-HIPEC; written informed consent.
Exclusion: none; Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.